Colin Angle was diving off the coast of Bermuda with his wife, Erika, when he saw some unusual fish: bright stripes, big spines, slow-moving.
The captain of their boat said they were lionfish, an invasive species that has been wreaking havoc... Read more »
A funny thing happened in the five years since Amazon acquired warehouse automation firm Kiva Systems for $775 million. The logistics robot market has taken off, with different competing systems shuttling inventory around to try to speed up order fulfillment. But... Read more »
Austin—Texas Rep. Lamar Smith has long said he doesn’t believe in man-made climate change. But it was only in this last year of “fake news” and “alternative facts” that that sentiment moved Joseph Kopser to take action.
“He doesn’t believe... Read more »
The Indiana Biosciences Research Institute (IBRI), a nonprofit, industry-led life sciences research institute focused on targeting cardio-metabolic diseases, diabetes and poor nutrition, has a new collaborative project underway.
The IBRI is teaming up with Eli Lilly and Dow AgroSciences to create... Read more »
[Updated 3/28/17, 9:02 a.m. See below.] This week in Boston tech, we’re tracking new venture funds, the latest startup investments, the end of the road for some local companies, and more. Read on for details.
—Southern New Hampshire University... Read more »
Another large insurer has said it will cover Cologuard, a stool-based DNA screening test for colorectal cancer developed by Madison, WI-based Exact Sciences. The announcement sent the company’s stock price higher during trading Monday.
Hartford, CT-based Aetna (NYSE: AET) updated... Read more »
An ovarian cancer drug from Tesaro has won FDA approval ahead of schedule, adding a third treatment to a new group of therapies that work by blocking a process that tumors use to repair themselves.
Waltham, MA-based Tesaro (NASDAQ: TSRO)... Read more »
ONL Therapeutics, the Ann Arbor, MI-based biotech startup working on sight-preserving therapies for patients with retinal diseases, is one step closer to clinical trials, thanks to a cash infusion from the National Eye Institute (NEI).
Last week, the NEI awarded ONL... Read more »
If you keep hearing your tech-savvy colleagues and friends using the term “blockchain,” but still feel like you don’t quite understand what they’re referring to, you’re not the only one. Even top executives at large financial services firms are still getting... Read more »
Akcea Therapeutics, an Ionis Pharmaceuticals subsidiary focused on rare lipid disorders, is spinning out of its parent with plans for an initial public stock offering as it prepares to file for FDA approval for its lead drug.
The Akcea stock offering... Read more »
Hard to believe, but we’re just a day away from Robo Madness 2017, our third annual Boston conference on robotics and artificial intelligence. It’s all happening at Google’s offices in Kendall Square tomorrow afternoon. The full agenda is here.... Read more »
San Antonio—For many entrepreneurs who leave their business, investing is an easy next step. That’s what Lew Moorman did after he left Rackspace in 2013. But he didn’t like it.
“I found myself not enjoying my day. I was spending... Read more »
Last week, Xconomy published a story about how I jammed with Bullhorn CEO Art Papas in the music room at his software company’s downtown Boston headquarters. Hard-hitting journalism, I know.
But our meeting wasn’t just about rocking out to a Foo... Read more »